Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XELOX · 1 trial · 1 indication
Area under the serum concentration-time curve per week, at steady state (AUCss per week). Estimation of the parameter was performed using non-compartmental methods.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bevacizumab [Avastin] | DRUG | 7.5mg/kg iv on day 1 of each 3 week cycle |
| XELOX | DRUG | As prescribed |
| FOLFOX-4 | DRUG | As prescribed |
Inclusion Criteria: * adult patients, \>=18 years of age; * adenocarcinoma of the colon or rectum, with metastatic or locally advanced disease; * \>=1 target lesion. Exclusion Criteria: * patients who have previously received systemic treatment for advanced or metastatic disease; * patients who h...
Top 20 of 77 competitors
XELOX is a chemotherapy regimen used for colorectal cancer, specifically studied in metastatic colorectal cancer. It is a combination treatment evaluated in a Phase 3 clinical trial. The drug is developed by Roche Holding AG and is in the oncology therapeutic area.
XELOX is a small molecule modality. The specific molecular target is not provided in the available information. It is used in combination with Avastin (bevacizumab) in the treatment of metastatic colorectal cancer, as studied in clinical trials.
XELOX is developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical development of this chemotherapy regimen for colorectal cancer.
XELOX is in Phase 3 clinical development. It has completed one Phase 3 trial, NCT00349336, which evaluated the drug in combination with Avastin (bevacizumab) in patients with metastatic colorectal cancer. The trial is completed, and XELOX remains an investigational regimen.
XELOX has one completed Phase 3 clinical trial, NCT00349336, titled "A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer." The trial enrolled 64 participants and was conducted in Australia, Canada, and New Zealand.
XELOX is a combination chemotherapy regimen that includes capecitabine and oxaliplatin. The available information does not provide alternative names for XELOX, but it is commonly known as a regimen combining these two agents for colorectal cancer treatment.